These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32672361)

  • 1. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
    Liu X; Liu D; Pan Y; Li Y
    J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.
    Gioia F; Gomez-Lopez A; Alvarez ME; Gomez-García de la Pedrosa E; Martín-Davila P; Cuenca-Estrella M; Moreno S; Fortun J
    Int J Infect Dis; 2020 Dec; 101():24-28. PubMed ID: 32937195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.
    Brüggemann RJ; Middel-Baars V; de Lange DW; Colbers A; Girbes AR; Pickkers P; Swart EL
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity.
    Gil-Alonso S; Quindós G; Cantón E; Eraso E; Jauregizar N
    Rev Iberoam Micol; 2019; 36(1):24-29. PubMed ID: 30837186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous Mutational Frequency and
    Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
    Kofla G; Ruhnke M
    Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an
    Siopi M; Perlin DS; Arendrup MC; Pournaras S; Meletiadis J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of the three echinocandins in ICU patients.
    Mainas E; Apostolopoulou O; Siopi M; Apostolidi S; Neroutsos E; Mirfendereski H; Marchand S; Couet W; Dokoumetzidis A; Valsami G; Sambatakou H; Dimopoulos G; Meletiadis J
    J Antimicrob Chemother; 2020 Oct; 75(10):2969-2976. PubMed ID: 32696036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
    Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2008 Jan; 52(1):321-8. PubMed ID: 17938191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
    Gumbo T
    Curr Opin Infect Dis; 2007 Dec; 20(6):587-91. PubMed ID: 17975408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
    Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical review of echinocandins in pediatric patients.
    VandenBussche HL; Van Loo DA
    Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
    Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.